HLA-C and ovarian cancer: In a Phase 1 study, 9 participants with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma were administered with 5 class I MHC-restricted synthetic peptides derived from multiple ovarian cancer-associated proteins, as well as a class II MHC-restricted synthetic helper peptide derived from tetanus toxoid protein.